Insider Trading March 26, 2026

Exzeo CEO Paresh Patel Buys $29,620 in Company Stock as Shares Trade Near Year Low

Insider adds 2,000 shares while holding multi-million share position and sizeable option package; recent earnings met estimates

By Marcus Reed XZO
Exzeo CEO Paresh Patel Buys $29,620 in Company Stock as Shares Trade Near Year Low
XZO

Exzeo Group Chief Executive Officer Paresh Patel purchased 2,000 shares of company common stock at $14.81 per share on March 25, 2026, a $29,620 outlay that leaves him with direct ownership of 1,586,013 shares. The trade took place while the stock traded close to its 52-week low and after the company reported fourth-quarter and full-year 2025 results that matched analyst forecasts.

Key Points

  • CEO Paresh Patel purchased 2,000 Exzeo Group shares at $14.81 per share on March 25, 2026, totaling $29,620.
  • After the purchase Patel directly owns 1,586,013 shares and holds options to buy 5,000,000 shares at a $23 exercise price, granted on October 1, 2021 and vesting from October 1, 2022.
  • Exzeo reported Q4 and full-year 2025 results with diluted EPS of $0.25 and quarterly revenue of $53.32 million, matching analyst forecasts; valuation metrics in the filing show a P/E of 16.13 and a PEG of 0.14, with analyst price targets between $25 and $27.

Exzeo Group, Inc. reported an insider purchase by Chief Executive Officer Paresh Patel who acquired 2,000 shares of the companys common stock at $14.81 per share, for a total of $29,620. The transaction, disclosed in a Form 4 filed with the Securities and Exchange Commission, was executed on March 25, 2026.

Following the purchase, Patel directly holds 1,586,013 shares of Exzeo Group common stock. The trade occurred while the shares were trading near their 52-week low of $12.91 and after the stock had declined roughly 40 percent year-to-date.

The Form 4 filing also details Patels option holdings: he possesses options to buy 5,000,000 shares of Exzeo Group common stock at an exercise price of $23 per share. Those options were granted on October 1, 2021, and began vesting in installments starting October 1, 2022.

Market-value metrics cited in the filing point to a relatively low price-to-earnings ratio of 16.13 against near-term earnings growth, and an appealing price/earnings-to-growth ratio of 0.14. Analyst price targets referenced in the filing ranged from $25 to $27.

In related corporate disclosures, Exzeo Group announced its fourth-quarter and full-year 2025 financial results. The company reported diluted earnings per share of $0.25 and quarterly revenue of $53.32 million. Those results were in line with analyst expectations, and subsequent aftermarket trading showed an uptick in the companys shares.

While the stock reaction after the earnings release was positive in aftermarket trading, the filing emphasizes that the financial results were consistent with forecasts. The CEOs recent purchase supplements a substantial existing direct holding and is accompanied by a large option grant outstanding with an exercise price above the current trading level.

The transaction and the disclosures together provide a snapshot of insider positioning and the companys recent operating results. The purchase documents, options schedule, valuation ratios, analyst targets, and the companys reported quarterly figures are all presented in the regulatory filings that accompanied the disclosure.

Readers should note that the facts above come from the companys public filings and the financial figures reported in the earnings release; the filings show the timing, scale, and terms of the insider purchase as well as the outstanding option position.

Risks

  • The stock was trading near its 52-week low of $12.91 and is down about 40% year-to-date, indicating recent price weakness that may affect investors' near-term returns.
  • Patels outstanding options carry an exercise price of $23 per share, which is above the current trading level reported in the filing, creating uncertainty about future option exercise timing and potential share count changes.
  • Although fourth-quarter and full-year 2025 results met forecasts, reliance on results that simply align with expectations leaves limited immediate upside tied solely to earnings surprises.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026